Invicta Diagnostic Ltd (INVICTA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 0 | NSE: INVICTA | Hospital & Healthcare Services | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Invicta Diagnostic

Based on:

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Invicta Diagnostic stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
20.77
Market Cap:
108.6 Cr.
52-wk low:
0
52-wk high:
0

Is Invicta Diagnostic Ltd an attractive stock to invest in?

1. Is Invicta Diagnostic Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Invicta Diagnostic Ltd is a below average quality company.

2. Is Invicta Diagnostic Ltd undervalued or overvalued?

The key valuation ratios of Invicta Diagnostic Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Invicta Diagnostic Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Invicta Diagnostic Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Invicta Diagnostic:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Invicta Diagnostic Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'24Mar'25TTM
ROCE % 50%55.7%-
Value Creation
Index
2.63.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 9.716.316
Sales YoY Gr.-68.1%-
Adj EPS 4.86.24.2
YoY Gr.-30.5%-
BVPS (₹) 915.233.2
Adj Net
Profit
45.25
Cash Flow from Ops. 3.32.8-
Debt/CF from Ops. 0.60.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANANA68.1%
Adj EPS NANANA30.5%
BVPSNANANA69%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'24Mar'25TTM
Return on
Equity %
5351.417.2
Op. Profit
Mgn %
40.738.1NAN
Net Profit
Mgn %
41.432.132.1
Debt to
Equity
0.30.2-
Working Cap
Days
0710
Cash Conv.
Cycle
0150

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 17.20%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Invicta Diagnostic Ltd.

Standalone Consolidated
TTM EPS (₹) 4.2 3.9
TTM Sales (₹ Cr.) 16.3 30.1
BVPS (₹.) 33.2 34.7
Reserves (₹ Cr.) 29 31
P/BV 2.60 2.49
PE 20.77 22.19
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 109
Equity (₹ Cr.) 12.6
Face Value (₹) 10
Industry PE 88.4

Management X-Ray of Invicta Diagnostic:

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Valuation of Invicta Diagnostic - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Invicta Diagnostic

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'24Mar'25
Sales1016
Operating Expenses 610
Manufacturing Costs24
Material Costs-0-0
Employee Cost 22
Other Costs 34
Operating Profit 46
Operating Profit Margin (%) 40.7%38.1%
Other Income 21
Interest 00
Depreciation 11
Exceptional Items 00
Profit Before Tax 57
Tax 11
Profit After Tax 45
PAT Margin (%) 41.4%32.1%
Adjusted EPS (₹)4.86.2
Dividend Payout Ratio (%)0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'24Mar'25

Equity and Liabilities

Shareholders Fund 813
Share Capital 08
Reserves 74
Minority Interest00
Debt22
Long Term Debt22
Short Term Debt00
Trade Payables10
Others Liabilities 13
Total Liabilities 1117

Fixed Assets

Gross Block99
Accumulated Depreciation45
Net Fixed Assets 54
CWIP 00
Investments 48
Inventories00
Trade Receivables12
Cash Equivalents 11
Others Assets 02
Total Assets 1117

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'24Mar'25
Cash Flow From Operating Activity 33
PBT 57
Adjustment -1-0
Changes in Working Capital -1-3
Tax Paid 00
Cash Flow From Investing Activity -3-3
Capex -0-0
Net Investments -4-4
Others 21
Cash Flow From Financing Activity 0-0
Net Proceeds from Shares 00
Net Proceeds from Borrowing 2-0
Interest Paid -0-0
Dividend Paid 00
Others -1-0
Net Cash Flow 1-0

Finance Ratio

PARTICULARSMar'24Mar'25
Ratios
ROE (%)53.0251.41
ROCE (%)50.0155.65
Asset Turnover Ratio0.871.14
PAT to CFO Conversion(x)0.750.6
Working Capital Days
Receivable Days2835
Inventory Days117
Payable Days-933-2,691

Invicta Diagnostic Ltd Stock News

Invicta Diagnostic Ltd FAQs

The current trading price of Invicta Diagnostic on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Invicta Diagnostic stood at ₹108.6.
The latest P/E ratio of Invicta Diagnostic as of 31-Dec-1969 is 20.77.
The latest P/B ratio of Invicta Diagnostic as of 31-Dec-1969 is 2.60.
The 52-week high of Invicta Diagnostic is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Invicta Diagnostic is ₹16.27 ( Cr.) .

About Invicta Diagnostic Ltd

Invicta Diagnostic Limited was incorporated as Limited Liability Partnership under the name ‘Invicta Diagnostic LLP’ on January 22, 2021. Further, Invicta Diagnostic LLP was converted into a private limited company ‘Invicta Diagnostic Private Limited’ on December 1, 2023. Subsequently, the company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of the shareholders held on April 20, 2024 and the name of the company was changed to ‘Invicta Diagnostic Limited’ on July 2, 2024.

The company is a diagnostic chain in Mumbai Metropolitan Region (MMR) offering radiology and pathology solutions. It offers pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory and teleradiology to customers under the brand name ‘PC Diagnostics’ through its operational network, which consists of diagnostic centres and centralised laboratory across Mumbai Metropolitan Region in the state of Maharashtra. 

It has implemented a ‘hub and spoke’ model across MMR which are either directly or through its subsidiaries, whereby specimens are collected across multiple locations within a catchment area or region for delivery to the company’s reference centres for diagnostic testing. This model provides greater economies of scale and enhances consistency in its testing procedures and results. All of its centres offer integrated diagnostics services (pathology and radiology tests under one roof) with smaller spokes offering pathology tests and basic radiology tests and hub centres offering pathology tests, basic radiology tests and advanced radiology tests such as MRI, CT and PET CT.

Business area of the company

The company is primarily engaged in the service of diagnostic chain offering comprehensive radiology and pathology solutions. 

Services of the company

Radiology 

  • Basic Radiology Tests - Its basic radiology tests include ECG, X-rays, and ultrasounds.
  • Advanced Radiology Tests - Its advanced radiology tests include CT scans and MRI scans and highly specialized nuclear medicine tests such PET-CT scans, which require advanced machinery to conduct such tests.

Pathology

  • Routine Testing - Its routine tests include basic biochemistry, basic haematology, clinical pathology which are performed at its own centres and surgical/anatomic pathology, microbiology and cytology tests are outsourced to reference laboratories.
  • Specialized Testing - Its specialized test includes advanced biochemistry, chemiluminescence immunoassay (CLIA) that combine chemiluminescence technique with immunochemical reactions.

Awards, accreditations and recognition 

  • 2024: Recipient at the Great Indian Healthcare Leaders’ Summit and Awards 2024 under the category of ‘Great Indian Radiology Centre’.

History and milestones

  • 2021: Incorporation of Erstwhile LLP.
  • 2021: Setting up of 1st fully integrated Diagnostic Centre in Thane having the entire gamut of services under its umbrella including PET CT scans, CT scans, MRI Scans, Sonography, X-Ray and Pathology.
  • 2023: Conversion of Erstwhile LLP into a private limited company ‘Invicta Diagnostic Private Limited’ pursuant to the provisions of Chapter XXI of the Companies Act, 2013.
  • 2023: Acquisition of majority shareholding in ‘PCD Diagnostics LLP’ for a full-fledged diagnostic centre in Marol, Andheri East, forming it as the company’s subsidiary.
  • 2023: Acquisition of majority shareholding in ‘Primacare Healthcare LLP’ for a full-fledged diagnostic centre in Byculla, forming it as the company’s subsidiary.
  • 2023: Acquisition of majority shareholding in ‘Pratham MRI and CT Scan Centre’ for a full-fledged diagnostic centre in Bhayandar, forming it as the company’s subsidiary.
  • 2024: Acquisition of a diagnostic centre in Sewri from PCD Medical LLP.
  • 2024: Acquisition of a diagnostic centre in Parel from Primacare Diagnostic LLP.
  • 2024: Acquisition of a centralised laboratory in Parel from Porteus Path Lab LLP.
  • 2024: Formation of the subsidiary ‘Invicta Medical LLP’ for setting up of diagnostic centre in Kalwa, Thane. 
  • 2024: Conversion from Private Limited to Public Limited Company.
  • 2025: Acquisition of ‘Porteus Medical LLP’ (Formerly known as ‘Porteus Porteus Path Lab LLP’) for forming it as the company’s subsidiary.
  • 2025: Acquisition of ‘Primacare Diagnostic LLP’ for setting up of diagnostic centre in Dadar, Mumbai, forming it as the company’s subsidiary.
  • 2025: Acquisition of ‘MSCRIBEIT Infotech LLP’ (Formerly Knowns as ‘PCD Medical LLP’) forming it as the company’s Associate.

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×